The short version of peptide purity fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
== Solid-phase peptide synthesis (SPPS) == Solid-phase synthesis is a common technique for peptide synthesis. Usually, peptides are synthesised from the carbonyl group side (C-terminus) to amino group side (N-terminus) of the amino acid chain in the SPPS method, although peptides are biologically synthesised in the opposite direction in cells. In peptide synthesis, an amino-protected amino acid is bound to a solid phase material or resin (most commonly, low cross-linked polystyrene beads), forming a covalent bond between the carbonyl group and the resin, most often an amido or an ester bond. Then the amino group is deprotected and reacted with the carbonyl group of the next N-protected amino acid. The solid phase now bears a dipeptide. This cycle is repeated to form the desired peptide chain. After all reactions are complete, the synthesised peptide is cleaved from the bead. The protecting groups for the amino groups mostly used in the peptide synthesis are 9-fluorenylmethyloxycarbonyl group (Fmoc) and t-butyloxycarbonyl (Boc). A number of amino acids bear functional groups in the side chain which must be protected specifically from reacting with the incoming N-protected amino acids. In contrast to Boc and Fmoc groups, these have to be stable over the course of peptide synthesis although they are also removed during the final deprotection of peptides.
The image of seedy underground, destitute smokers were often generated by anti-opium narratives and became a more accurate image of opium use following the effects of large scale opium prohibition in the 1880s.
Biden declared his candidacy for the 1988 Democratic presidential nomination on June 9, 1987. He was considered a strong candidate because of his moderate image, his speaking ability, his high profile as chair of the Senate Judiciary Committee at the upcoming Robert Bork Supreme Court nomination hearings, and his appeal to Baby Boomers. He raised more in the first quarter of 1987 than any other candidate. By August, Biden's campaign messaging had become confused due to staff rivalries, and in September, he was accused of plagiarizing a speech by British Labour Party leader Neil Kinnock. Biden had credited Kinnock on previous occasions, but did not on two occasions in August. Earlier that year, Biden had also used passages from a speech by Robert F. Kennedy (for which his aides took blame) and the inaugural address of John F. Kennedy. Two years earlier he had used a 1976 passage by Hubert Humphrey. Biden responded that politicians often borrow from one another without giving credit, and that one of his rivals for the nomination, Jesse Jackson, had called him to point out that Jackson had used the same material by Humphrey that Biden had used. A few days later, it was publicized that, while in law school, Biden had taken text from a Fordham Law Review article with inadequate citations. At Biden's request the Delaware Supreme Court's Board of Professional Responsibility reviewed the incident and concluded that he had violated no rules.
Sources: en.wikipedia.org
=== Paralogs === Troponin is found in both skeletal muscle and cardiac muscle, but the specific versions of troponin differ between types of muscle. Different combinations of paralogous genes (vaguely called "isoforms", not to be confused with gene isoforms) are used to make the version of troponin seen in each type of muscle.
After scoring a hit with the recording, he looked to Cornelius to help him put together an actual group to maintain the impact. In 1977, Soul Train dancers Jody Watley and Jeffrey Daniels and former Soul Train Gang member Gerald Brown (who was eventually replaced by Howard Hewett) were recruited to form the new Shalamar, which would become the fledgling label's centerpiece. Cornelius wanted to shut down the label and Griffey paid him $300,000 for his interests in the label. Cornelius wanted to focus his energies on the TV show — which was a monster hit and required his full attention to keep it so. With legalities now taken care of, Griffey reorganized Soul Train Records into the newly founded SOLAR label in late 1977. Griffey and Cornelius remained good friends, and as a result SOLAR maintained close ties to the Soul Train show.
=== Thioredoxin reductase === Thioredoxin reductase is also a key component of antioxidant defense. Although enzymes carrying out this function is found in most forms of life, the high-molecular-weight selenoprotein version found in animals evolved separately from the more common low-molecular-weight version. This version appears as a branch within the glutathione reductases, again a key component of antioxidant defense.
Under the United States Federal Analogue Act, compounds which are analogues of and "substantially similar" to Schedule I and Schedule II controlled substances may themselves be treated as Schedule I controlled substances. Consequent to this law, such substances may be considered illegal to sell, purchase, or possess. However, the law applies only if the compounds are intended for human consumption. The Federal Analogue Act has been considered "void for vagueness" as the meaning of "substantially similar" is not precisely defined. In addition, the law only applies to compounds explicitly intended for human consumption. As a result, if compounds are not marketed this way, they can still be legally sold. This has resulted in such compounds being marketed as "research chemicals", "bath salts", "plant food", and "not for human consumption", even though they actually are intended for human use. Such flaws have limited the law and led to calls for reform.
Sources: en.wikipedia.org
On December 13, 2018, the teaser of the film Black Antenna featuring the song "Rainier Fog" was released on Alice in Chains' official YouTube channel, with drummer Sean Kinney stating; "We've always toyed with the idea of creating videos for every song on one of our albums. Not only did we do that for Rainier Fog, it got totally out of hand and we made a whole goddamn movie. Everything that will be seen in the videos will be footage from Black Antenna to preface the complete film's release." "Rainier Fog" was released as a single on February 26, 2019. The official trailer for Black Antenna was released on Alice in Chains' YouTube Channel on February 28, 2019. Besides a 90-minute film, a 10-part web-series focused on each track from the album was planned. Episodes 1 and 2, "The One You Know" and "Rainier Fog", respectively, were released on March 7, 2019. The tenth and last episode, "All I Am", was released on July 17, 2019. The official music video for "Rainier Fog" was released on YouTube on May 15, 2019, and was co-directed by Alice in Chains and Peter Darley Miller, who also directed the band's 2013 mockumentary, AIC 23. On December 1, 2020, Alice in Chains was honored with the Founders Award from Seattle's Museum of Pop Culture. The benefit concert featured tribute performances from artists such as Ann Wilson, Korn, Metallica, Fishbone, Dallas Green, Billy Corgan, Tad Doyle, members of Soundgarden and Pearl Jam, among others. The event was made available for streaming for free and raised more than $600,000 for the museum in its first night.
In September 1936, Fry's released an aerated Crunchie bar made entirely of chocolate. They justified this move as not breaching the patent, saying it was not a block but a bar. As Aero sales began to dip, Rowntree's brought out variants, selling the first aerated chocolates with fruit and nut inclusions. After Fry's launched a second aerated chocolate in August 1937 called Ripple, Rowntree's had to decide whether they wanted to try to enforce their patent. By this time, Nestlé and Fry's had joined Cadbury in having expressed a willingness to challenge the patent in the courts despite it being officially approved by the patent office. On legal advice that there was a 50% likelihood of success in a court challenge, and the threat of court proceedings causing bad publicity, Rowntree's entered negotiations with other chocolate makers to discuss licensing aerated chocolate. Rival companies were dominant in the proceedings dialogues, and Rowntree's ultimately agreed to licence aerated chocolate from June 1938 under the conditions that chocolate makers pay a sum with the release of new aerated chocolate lines and a 0.5% royalty on sales. After this agreement was put in place, Cadbury only released aerated chocolate products in overseas dominions where Aero was not established. Nestlé-produced aerated chocolates included a chocolate called Bubblo, made in the UK for export to New Zealand under a New Zealand patent. Aerated chocolate was already being sold in some overseas markets, by 1936 for instance, Aero was being successfully exported to Australia.
== External links == The Miller–Urey experiment website, a simulation of the Miller–Urey Experiment along with a video interview with Stanley Miller] by Scott Ellis from CalSpace (UCSD) Origin-Of-Life Chemistry Revisited: Reanalysis of famous spark-discharge experiments reveals a richer collection of amino acids were formed. Miller–Urey experiment explained Miller experiment with Lego bricks "Stanley Miller's Experiment: Sparking the Building Blocks of Life" on PBS Cairns-Smith, A.G. (1966). "The origin of life and the nature of the primitive gene". Journal of Theoretical Biology. 10 (1): 53–88. Bibcode:1966JThBi..10...53C. doi:10.1016/0022-5193(66)90178-0. PMID 5964688. Details of 2008 re-analysis
Estrogen has been found to increase the secretion of oxytocin and to increase the expression of its receptor, the oxytocin receptor, in the brain. In women, a single dose of ethinylestradiol has been found to be sufficient to increase circulating oxytocin concentrations.
=== Heart arrhythmia === Lidocaine is a common class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine preventive dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.